Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is 11.95% higher on its value in year-to-date trading and has touched a low of $0.35 and a high of $1.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DFFN stock was last observed hovering at around $0.92 in the last trading session, with the day’s loss setting it -0.03% off its average median price target of $2.00 for the next 12 months. It is also 55.5% off the consensus price target high of $2.00 offered by 1 analysts, but current levels are 55.5% higher than the price target low of $2.00 for the same period.
Currently trading at $0.89, the stock is -8.35% and -21.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.55 million and changing -3.44% at the moment leaves the stock -8.30% off its SMA200. DFFN registered 117.07% gain for a year compared to 6-month gain of 8.54%. The firm has a 50-day simple moving average (SMA 50) of $1.0658 and a 200-day simple moving average (SMA200) of $0.9383.
The stock witnessed a -0.69% loss in the last 1 month and extending the period to 3 months gives it a 11.95%, and is -3.26% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.73% over the week and 8.92% over the month.
Distance from 52-week low is 153.49% and -51.89% from its 52-week high.
Diffusion Pharmaceuticals Inc. (DFFN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Diffusion Pharmaceuticals Inc. (DFFN) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 3.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Diffusion Pharmaceuticals Inc. quarterly earnings per share for the current quarter are estimated at -$0.04.The EPS is expected to grow by 83.00% this year.
Diffusion Pharmaceuticals Inc. (DFFN) Top Institutional Holders
24 institutions hold shares in Diffusion Pharmaceuticals Inc. (DFFN), with 136.55k shares held by insiders accounting for 0.13% while institutional investors hold 6.57% of the company’s shares. The shares outstanding are 101.90M, and float is at 101.72M with Short Float at 2.19%. Institutions hold 6.56% of the Float.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 2.83 million shares valued at $2.25 million. The investor’s holdings represent 2.78% of the DFFN Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 0.83 million shares valued at $0.66 million to account for 0.81% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 0.39 million shares representing 0.39% and valued at over $0.31 million, while Geode Capital Management, LLC holds 0.25% of the shares totaling 0.26 million with a market value of $0.2 million.
Diffusion Pharmaceuticals Inc. (DFFN) Insider Activity
The most recent transaction is an insider purchase by ELDER WILLIAM ROBERT ,the company’sGC & Secretary. SEC filings show that ELDER WILLIAM ROBERT bought 5,000 shares of the company’s common stock on Nov 17 at a price of $0.63 per share for a total of $3150.0. Following the purchase, the insider now owns 15000.0 shares.
Diffusion Pharmaceuticals Inc. disclosed in a document filed with the SEC on Nov 16 that Cobuzzi Robert Joseph Jr. (President & CEO) bought a total of 14,000 shares of the company’s common stock. The trade occurred on Nov 16 and was made at $0.66 per share for $9240.0. Following the transaction, the insider now directly holds 14000.0 shares of the DFFN stock.
Still, SEC filings show that on Nov 16, ELDER WILLIAM ROBERT (GC & Secretary) acquired 10,000 shares at an average price of $0.67 for $6700.0. The insider now directly holds 10,000 shares of Diffusion Pharmaceuticals Inc. (DFFN).